SG11201807868VA - Transfected t-cells and t-cell receptors for use in immunotherapy against cancers - Google Patents
Transfected t-cells and t-cell receptors for use in immunotherapy against cancersInfo
- Publication number
- SG11201807868VA SG11201807868VA SG11201807868VA SG11201807868VA SG11201807868VA SG 11201807868V A SG11201807868V A SG 11201807868VA SG 11201807868V A SG11201807868V A SG 11201807868VA SG 11201807868V A SG11201807868V A SG 11201807868VA SG 11201807868V A SG11201807868V A SG 11201807868VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cells
- present description
- cell receptors
- peptides
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 7
- 108091008874 T cell receptors Proteins 0.000 title abstract 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 6
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 5
- 238000009169 immunotherapy Methods 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464488—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662308975P | 2016-03-16 | 2016-03-16 | |
GBGB1604492.7A GB201604492D0 (en) | 2016-03-16 | 2016-03-16 | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
PCT/EP2017/056260 WO2017158103A1 (fr) | 2016-03-16 | 2017-03-16 | Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807868VA true SG11201807868VA (en) | 2018-10-30 |
Family
ID=55952417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807868VA SG11201807868VA (en) | 2016-03-16 | 2017-03-16 | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
Country Status (16)
Country | Link |
---|---|
US (1) | US10538573B2 (fr) |
EP (1) | EP3430030B1 (fr) |
JP (1) | JP7340127B2 (fr) |
KR (2) | KR102457504B1 (fr) |
CN (1) | CN108884136B (fr) |
AU (2) | AU2017235467B2 (fr) |
CA (1) | CA3017502A1 (fr) |
CR (1) | CR20180492A (fr) |
EA (1) | EA201892021A1 (fr) |
GB (1) | GB201604492D0 (fr) |
MA (2) | MA43330B1 (fr) |
MX (1) | MX2018011225A (fr) |
MY (1) | MY189042A (fr) |
SG (1) | SG11201807868VA (fr) |
TW (1) | TWI764886B (fr) |
WO (1) | WO2017158103A1 (fr) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI721929B (zh) | 2013-08-05 | 2021-03-11 | 美商扭轉生物科技有限公司 | 重新合成之基因庫 |
CA2975852A1 (fr) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Procedes et dispositifs pour assemblage de novo d'acide oligonucleique |
WO2016172377A1 (fr) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Dispositifs et procédés pour la synthèse de banques d'acides oligonucléiques |
IL258164B (en) | 2015-09-18 | 2022-09-01 | Twist Bioscience Corp | Methods to regulate the activity of proteins and cells and a method for the production of nucleic acids |
WO2017053450A1 (fr) | 2015-09-22 | 2017-03-30 | Twist Bioscience Corporation | Substrats flexibles pour synthèse d'acide nucléique |
CN108603307A (zh) | 2015-12-01 | 2018-09-28 | 特韦斯特生物科学公司 | 功能化表面及其制备 |
TWI826891B (zh) * | 2016-03-16 | 2023-12-21 | 德商英麥提克生物技術股份有限公司 | 轉染 t 細胞和 t 細胞受體用於癌症免疫治療 |
WO2018038772A1 (fr) | 2016-08-22 | 2018-03-01 | Twist Bioscience Corporation | Banques d'acides nucléiques synthétisés de novo |
JP6871364B2 (ja) | 2016-09-21 | 2021-05-12 | ツイスト バイオサイエンス コーポレーション | 核酸に基づくデータ保存 |
DE102016123847B3 (de) * | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
PL3551221T3 (pl) | 2016-12-08 | 2022-02-28 | Immatics Biotechnologies Gmbh | Nowe receptory komórek t i immunoterapia z ich zastosowaniem |
EA201991262A1 (ru) * | 2016-12-16 | 2020-04-07 | Твист Байосайенс Корпорейшн | Библиотеки вариантов иммунологического синапса и их синтез |
SG11201907713WA (en) | 2017-02-22 | 2019-09-27 | Twist Bioscience Corp | Nucleic acid based data storage |
EP3595674A4 (fr) | 2017-03-15 | 2020-12-16 | Twist Bioscience Corporation | Banques de variants de la synapse immunologique et leur synthèse |
CA3059644A1 (fr) * | 2017-04-10 | 2018-10-18 | Immatics Biotechnologies Gmbh | Peptides et combinaisons de peptides destines a etre utilises en immunotherapie anticancereuse |
WO2018231864A1 (fr) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Méthodes d'assemblage d'acides nucléiques continus |
CN111566209A (zh) | 2017-06-12 | 2020-08-21 | 特韦斯特生物科学公司 | 无缝核酸装配方法 |
US11407837B2 (en) | 2017-09-11 | 2022-08-09 | Twist Bioscience Corporation | GPCR binding proteins and synthesis thereof |
WO2019075385A1 (fr) * | 2017-10-12 | 2019-04-18 | Board Of Regents, The University Of Texas System | Compositions de lymphocytes t pour l'immunothérapie |
KR20240024357A (ko) | 2017-10-20 | 2024-02-23 | 트위스트 바이오사이언스 코포레이션 | 폴리뉴클레오타이드 합성을 위한 가열된 나노웰 |
US10936953B2 (en) | 2018-01-04 | 2021-03-02 | Twist Bioscience Corporation | DNA-based digital information storage with sidewall electrodes |
GB201803750D0 (en) | 2018-03-08 | 2018-04-25 | Immunocore Ltd | Method |
WO2019196088A1 (fr) * | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Procédés d'obtention de récepteurs de lymphocytes t spécifiques d'une tumeur |
KR20210013128A (ko) | 2018-05-18 | 2021-02-03 | 트위스트 바이오사이언스 코포레이션 | 핵산 하이브리드화를 위한 폴리뉴클레오타이드, 시약 및 방법 |
MX2021003051A (es) * | 2018-09-14 | 2021-05-27 | Immatics Biotechnologies Gmbh | Metodo para el cribado de alto desempe?o de la afinidad mhc-peptido para ligandos tcr mediante complejos mhc libres de peptidos estabilizados. |
SG11202109283UA (en) | 2019-02-26 | 2021-09-29 | Twist Bioscience Corp | Variant nucleic acid libraries for antibody optimization |
AU2020229349A1 (en) | 2019-02-26 | 2021-10-14 | Twist Bioscience Corporation | Variant nucleic acid libraries for GLP1 receptor |
DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
CN111748029B (zh) * | 2019-03-29 | 2022-12-13 | 苏州蓝马医疗技术有限公司 | 一种针对egfr l858r基因突变的特异性t细胞受体及其应用 |
CN111748028A (zh) * | 2019-03-29 | 2020-10-09 | 天津亨佳生物科技发展有限公司 | 一种针对egfr l858r基因突变的特异性t细胞受体及其应用 |
CA3139011A1 (fr) * | 2019-05-08 | 2020-11-12 | Medigene Immunotherapies Gmbh | Lymphocytes t genetiquement modifies |
PE20220164A1 (es) | 2019-05-27 | 2022-01-28 | Immatics Us Inc | Vectores viricos y uso de los mismos en terapias celulares adoptivas |
CN114585646A (zh) * | 2019-06-18 | 2022-06-03 | 里珍纳龙药品有限公司 | Mage-a4 t细胞受体及其使用方法 |
EP3987019A4 (fr) | 2019-06-21 | 2023-04-19 | Twist Bioscience Corporation | Assemblage de séquences d'acide nucléique basé sur des code-barres |
CN110357953B (zh) * | 2019-07-17 | 2022-05-03 | 深圳市因诺转化医学研究院 | 识别人巨细胞病毒pp65抗原的TCR |
JP2022542448A (ja) * | 2019-07-30 | 2022-10-03 | ユニバーシティー ヘルス ネットワーク | Mhcクラスii分子及びその使用方法 |
US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
DE102019121007A1 (de) * | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
MX2022010461A (es) | 2020-02-24 | 2022-12-13 | Immatics Us Inc | Metodos para expandir linfocitos t para el tratamiento de cancer y neoplasias malignas asociadas. |
DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
WO2022040631A1 (fr) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Procédés d'isolement de lymphocytes t sélectionnés cd8+ |
CN116457371A (zh) * | 2020-10-07 | 2023-07-18 | 多安生物治疗有限公司 | T细胞受体、包含t细胞受体的免疫细胞及其使用方法 |
JP2024502034A (ja) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス,アイエヌシー. | Cd8ポリペプチド、組成物、及びそれらの使用方法 |
DE102021100038A1 (de) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
CN115975003B (zh) * | 2021-03-09 | 2024-01-26 | 科士华(南京)生物技术有限公司 | Tcr、多肽、表达载体、宿主细胞、药物组合物和tcr获得方法 |
EP4326751A1 (fr) * | 2021-04-21 | 2024-02-28 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Récepteurs de lymphocytes t à restriction hla de classe i dirigés contre ras ayant une mutation q61k |
US20220356252A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
CN113337514B (zh) * | 2021-08-05 | 2021-10-29 | 卡瑞济(北京)生命科技有限公司 | Tcr表达构建体以及其制备方法和用途 |
US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
CN113773378B (zh) * | 2021-10-14 | 2023-11-03 | 深圳大学总医院 | T细胞受体及其应用 |
WO2023081461A1 (fr) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Procédés de génération de sphéroïdes cellulaires |
US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
WO2023137472A2 (fr) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systèmes et procédés de programmation de phénotypes de lymphocytes t par répression génique ciblée |
WO2023137471A1 (fr) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systèmes et procédés de programmation de phénotypes de lymphocytes t par activation génique ciblée |
WO2023148494A1 (fr) * | 2022-02-03 | 2023-08-10 | University College Cardiff Consultants Limited | Nouveau récepteur des lymphocytes t |
WO2023183758A2 (fr) * | 2022-03-19 | 2023-09-28 | Regeneron Pharmaceuticals, Inc. | Molécules multispécifiques ciblant cd3 et magea4 et leurs utilisations |
WO2023212697A1 (fr) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-15 liée à une membrane, polypeptides de cd8, cellules, compositions et leurs procédés d'utilisation |
WO2023212655A1 (fr) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Polypeptides d'il-12, polypeptides d'il-15, polypeptides d'il-18, polypeptides de cd8, compositions et leurs procédés d'utilisation |
WO2023212691A1 (fr) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Polypeptides récepteurs de tgfβ négatifs dominants, polypeptides cd8, cellules, compositions et leurs méthodes d'utilisation |
US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
WO2023250168A2 (fr) * | 2022-06-24 | 2023-12-28 | Amgen Inc. | Récepteurs de lymphocyte t spécifiques de magea4 |
WO2024036166A1 (fr) * | 2022-08-08 | 2024-02-15 | The University Of North Carolina At Chapel Hill | Molécules de récepteur de lymphocytes t bioorthogonales, leurs procédés de fabrication et d'utilisation |
WO2024064642A2 (fr) | 2022-09-19 | 2024-03-28 | Tune Therapeutics, Inc. | Compositions, systèmes et méthodes de modulation de fonction de lymphocyte t |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8003770B2 (en) | 2005-09-13 | 2011-08-23 | Mie University | T-cell receptor and nucleic acid encoding the receptor |
WO2008053573A1 (fr) * | 2006-10-30 | 2008-05-08 | National University Corporation Hokkaido University | Remède pour néoplasme malin |
EP3590530B1 (fr) | 2010-09-20 | 2021-12-29 | Biontech Cell & Gene Therapies Gmbh | Récepteurs de lymphocytes t spécifiques aux antigènes et épitopes de lymphocytes t |
WO2012135854A2 (fr) * | 2011-04-01 | 2012-10-04 | Memorial Sloan-Kettering Cancer Center | Anticorps contre des peptides cytosoliques |
CN103957930A (zh) * | 2011-08-31 | 2014-07-30 | 国立大学法人三重大学 | 癌症治疗用疫苗制剂 |
WO2013057596A1 (fr) | 2011-10-21 | 2013-04-25 | Atena Srl | Coussin anatomique à accumulateur pour le traitement thermique avec chaud ou froid |
GB2508414A (en) * | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
EP3572510B1 (fr) * | 2013-11-21 | 2022-09-21 | Repertoire Genesis Incorporation | Système d'analyse des répertoires des récepteurs des lymphocytes t et des lymphocytes b et leur utilisation dans le traitement et le diagnostic |
US10202640B2 (en) * | 2014-05-07 | 2019-02-12 | The Board Of Trustees Of The Leland Stanford Junior University | Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing |
-
2016
- 2016-03-16 GB GBGB1604492.7A patent/GB201604492D0/en not_active Ceased
-
2017
- 2017-03-16 SG SG11201807868VA patent/SG11201807868VA/en unknown
- 2017-03-16 WO PCT/EP2017/056260 patent/WO2017158103A1/fr active Application Filing
- 2017-03-16 TW TW106108700A patent/TWI764886B/zh active
- 2017-03-16 MY MYPI2018703216A patent/MY189042A/en unknown
- 2017-03-16 KR KR1020217015786A patent/KR102457504B1/ko active IP Right Grant
- 2017-03-16 CN CN201780017511.6A patent/CN108884136B/zh active Active
- 2017-03-16 US US15/460,654 patent/US10538573B2/en active Active
- 2017-03-16 MX MX2018011225A patent/MX2018011225A/es unknown
- 2017-03-16 JP JP2018548022A patent/JP7340127B2/ja active Active
- 2017-03-16 EP EP17710955.0A patent/EP3430030B1/fr active Active
- 2017-03-16 CR CR20180492A patent/CR20180492A/es unknown
- 2017-03-16 MA MA43330A patent/MA43330B1/fr unknown
- 2017-03-16 KR KR1020187029016A patent/KR102259109B1/ko active IP Right Grant
- 2017-03-16 MA MA043720A patent/MA43720A/fr unknown
- 2017-03-16 EA EA201892021A patent/EA201892021A1/ru unknown
- 2017-03-16 AU AU2017235467A patent/AU2017235467B2/en active Active
- 2017-03-16 CA CA3017502A patent/CA3017502A1/fr active Pending
-
2021
- 2021-07-07 AU AU2021204753A patent/AU2021204753A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3430030B1 (fr) | 2023-12-20 |
MA43720A (fr) | 2018-11-28 |
US10538573B2 (en) | 2020-01-21 |
JP2019511222A (ja) | 2019-04-25 |
MX2018011225A (es) | 2018-11-22 |
KR102259109B1 (ko) | 2021-06-01 |
EP3430030A1 (fr) | 2019-01-23 |
KR102457504B1 (ko) | 2022-10-20 |
CN108884136A (zh) | 2018-11-23 |
CA3017502A1 (fr) | 2017-09-21 |
KR20210063486A (ko) | 2021-06-01 |
CN108884136B (zh) | 2023-03-17 |
WO2017158103A1 (fr) | 2017-09-21 |
KR20180118783A (ko) | 2018-10-31 |
AU2017235467B2 (en) | 2021-04-08 |
CR20180492A (es) | 2019-01-31 |
MA43330A1 (fr) | 2019-07-31 |
TW201736396A (zh) | 2017-10-16 |
GB201604492D0 (en) | 2016-04-27 |
MY189042A (en) | 2022-01-21 |
AU2021204753A1 (en) | 2021-08-05 |
AU2017235467A1 (en) | 2018-11-01 |
EA201892021A1 (ru) | 2019-02-28 |
TWI764886B (zh) | 2022-05-21 |
MA43330B1 (fr) | 2020-06-30 |
US20170267738A1 (en) | 2017-09-21 |
JP7340127B2 (ja) | 2023-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807868VA (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
SG11201807590SA (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
SG11201806905UA (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
SG11201807300PA (en) | Uterine cancer treatments | |
SG11201806951TA (en) | Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers | |
SG11201900955VA (en) | T cell receptors and immune therapy using the same | |
SG11201806577UA (en) | Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers | |
SG11201908023YA (en) | T cell receptors and immune therapy using the same against prame positive cancers | |
SG11201906198PA (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
SG11201801384YA (en) | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | |
SG11201801670YA (en) | Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers | |
SG11201801756WA (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
SG11201909153UA (en) | Peptides and combination thereof for use in the immunotherapy against cancers | |
SG11201809781PA (en) | Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers | |
SG11201908527SA (en) | High affinity mage-a1-specific tcrs and uses thereof | |
SG11201808783XA (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
SG11201806150RA (en) | Psma and cd3 bispecific t cell engaging antibody constructs | |
SG11201807279QA (en) | Binding proteins and methods of use thereof | |
SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201804839WA (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
SG11201907580SA (en) | Combination therapies for treatment of bcma-related cancers and autoimmune disorders | |
SG11201810697QA (en) | Chimeric antigen receptor and car-t cells that bind bcma | |
SG11201808629UA (en) | Immunotherapy against melanoma and other cancers |